Alzheimer's/Dementia Archives - Purablis-Medicinal Tinctures with CBD, THCA and THC

Alzheimer’s/Dementia Marijuana Studies and

Alzheimer’s/Dementia Cannabis Research

09/27/2018

Author(s): Lisa M. Eubanks†, Claude J. Rogers†, Albert E. Beuscher IV‡, George F. Koob§, Arthur J. Olson‡, Tobin J. Dickerson†, and Kim D. Janda†.

THC competitively inhibits the enzyme acetylcholinesterase (AChE) and prevents the aggregation of amyloid β peptide induced by AChE (Aβ), the key pathological marker of Alzheimer’s disease. View study

09/27/2018

Author(s): IVÁN MANUEL, LAURA LOMBARDERO, FRANK M. LAFERLA, LYDIA GIMÉNEZ-LLORT AND RAFAEL RODRÍGUEZ PUERTAS.

The positive regulation of the galaninnergic and endocannabinoid systems supports the hypothesis of their neuroprotective functions, which are established before clear clinical cognitive symptoms of Alzheimer’s disease appear. View study

09/27/2018

Author(s): Krishnan S., Cairns R., Howard R.

Cannabinoids may have more positive and specific effects on the disruption of the disease process in Alzheimer’s disease. View study

09/27/2018

Author(s): Ester Aso, and Isidre Ferrer.

The cannabinoid compounds have polyvalent properties for the treatment of Alzheimer’s disease, which together promote progress towards a clinical trial. View study

09/27/2018

Author(s): Martín­Moreno AM , Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML.

Based on the results of this study it was found that cannabidiol (CBD) has the ability to modulate the function of the microglial cell in vitro, inducing beneficial effects in an in vivo model of Alzheimer’s disease, thus indicating that CBD has the potential to represent a new therapeutic approach to treat this disease. View study

09/27/2018

Author(s): Sebastian Walther . Richard Mahlberg . Uta Eichmann . Dieter Kunz.

Dronabinol reduces nocturnal motor activity and agitation in patients with severe dementia. Thus, it represents a great potential for the safe treatment of alterations in dementia. View study

09/27/2018

Author(s): Gaurav Bedsea,b, Adele Romanob, Angelo M. Lavecchiab, Tommaso Cassanoc,∗ and Silvana Gaetanib.

In this study, we summarize the role of endocannabinoid signaling in Alzeimer disease and the probable mechanisms through which modulators of the endocannabinoid system provide their effects, thus highlighting how this objective could provide more advantages than other therapeutic objectives. View study

09/27/2018

Author(s): Rosaliana Libro, Sabrina Giacoppo, Thangavelu Soundara Rajan, Placido Bramanti and Emanuela Mazzon *.

Properties and neuroprotective effects of the phytochemicals belonging to polyphenols, cannabinoids, alkaloids and isothiocyanates for the treatment and prevention of common types of dementia. View study

09/27/2018

Author(s): Attila Köfalvi1,2, Cristina Lemos1$, Ana M. Martín-Moreno3,4,# , Bárbara S. Pinheiro1$ , Luis García-García5 , Miguel A. Pozo5,6, Ângela Valério-Fernandes1 , Rui O. Beleza1 , Paula Agostinho1,7, Ricardo J. Rodrigues1,2, Susana J. Pasquaré3,7, Rodrigo A. Cunha1,8 , María L. de Ceballos3,4.

This study was conducted on CB2R cannabinoid receptors (CB2R) in order to analyze their potential as therapeutic targets. It was found that CB2R has a general role of glucoregulation in the brain, which increases the therapeutic interest in CB2R agonists as nootropic agents.View study

09/27/2018

Author(s): Shabbir Amanullah, Kristin MacDougall, Nichole Sweeney, Joan Coffin, Julie Cole.

A synthetic cannabinoid known as Nabilone improved psychomotor agitation, aggression and communication in patients with dementia, thus demonstrating the potential of cannabinoids in the treatment of these disorders. View study

09/27/2018

Author(s): S G Fagan and V A Campbell.

Modulation of the cannabinoid system has shown beneficial effects and constitutes a possibility for the treatment of neurodegenerative disorders such as Parkinson’s disease. View study